Shai Mulinari
1 – 10 of 46
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2018
- Categorical and anti-categorical approaches to US racial/ethnic groupings: revisiting the National 2009 H1N1 Flu Survey (NHFS)
- Sociodemographic patterns in pharmacy dispensing of medications for erectile dysfunction in Sweden
- Explaining biological depression theories
- Let the drugs lead the way! On the unfolding of a research programme in phychiatry
- Chronic Obstructive Pulmonary Disease in Sweden: an intersectional multilevel analysis of individual heterogeneity and discriminatory accuracy
- Regulatory scientists' work has important ramifications for public health and should be open to public scrutiny
- Disclosure of payments by pharmaceutical companies to healthcare professionals in the United Kingdom: analysis of the Association of the British Pharmaceutical Industry’s Disclosure UK database, 2015 and 2016 cohorts
- Sunshine Policies and Murky Shadows in Europe: Disclosure of Pharmaceutical Industry Payments to Health Professionals in Nine European Countries
- Pharmaceutical lobbying and pandemic stockpiling of Tamiflu: a qualitative study of arguments and tactics
- 2017
- Why European and United States drug regulators are not speaking with one voice on anti-influenza drugs: regulatory review methodologies and the importance of 'deep' product reviews